XML 21 R6.htm IDEA: XBRL DOCUMENT v3.26.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Cash flow from operating activities    
Net loss $ (10,364) $ (11,024)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation expense 319 842
Amortization of right of use asset 324 537
Amortization of intangible assets 19 5
Loss on disposal of subsidiary 25
Impairment of Armor 64 4,602
Stock based compensation – Employee 1,390 82
Stock based compensation – Non-employee 606
Change in fair value of derivative liabilities 124 (3,475)
Loss (gain) on disposal of equipment (352) 18
Bad debt expense (recoveries) (3) (1)
Changes in operating assets and liabilities:    
Account and other receivables (69) 490
Prepaid expenses and other assets (47) 482
Inventories (85) 72
Accounts payable and accrued liabilities (200) (756)
Other liabilities 45 (2)
Payments on operating lease liability (367) (514)
Net cash used in operating activities (8,571) (8,642)
Cash flows from investing activities    
Purchase of property and equipment (185) (690)
Disposal of property and equipment, net of cash received (4)
Proceeds from the sale of property and equipment 352 20
Proceeds from acquisition of Sinaptic Surgical 750
Proceeds from notes receivable, net of imputed interest 476
Net cash provided by (used in) investing activities 913 (194)
Cash flows from financing activities    
Proceeds from issuance of warrant derivative liabilities 3,366
Proceeds from issuance of common stock and prefunded warrants, net of cash fees 4,380 6,075
Proceeds from exercise of warrants, net of cash fees, and deposit for stock issuance (in other current liabilities) 3,624
Proceeds from issuance of common stock in connection with ATM, net of fees 329
Proceeds from issuance of warrants in connection with exercise of warrants 206
Purchase of common stock into treasury (133)
Proceeds from issuance of common stock in connection with exercise of warrants 2
Principal payment on debt (206) (349)
Net cash provided by financing activities 8,200 9,094
Net increase in cash and cash equivalents 542 258
Cash and cash equivalents at beginning of year 3,598 3,340
Cash and cash equivalents at end of year 4,140 3,598
Noncash investing and financing activities    
Reduction of derivative liability upon exercise of warrants 1
Deemed dividend related to warrant inducement and issuance of warrants 6,719
Right of use asset for amended lease liability – decrease 307
Debt issued for prepaid insurance 180 335
Agent warrant offering cost allocated to equity 13
Supplemental cash flow information    
Cash paid for interest $ 52 $ 29